Logo image of BCRX

BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Fundamental Analysis

NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD

8.93  +0.22 (+2.53%)

After market: 8.9 -0.03 (-0.34%)

Fundamental Rating

3

Overall BCRX gets a fundamental rating of 3 out of 10. We evaluated BCRX against 563 industry peers in the Biotechnology industry. BCRX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BCRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BCRX had negative earnings in the past year.
In the past year BCRX has reported a negative cash flow from operations.
BCRX had negative earnings in each of the past 5 years.
BCRX had a negative operating cash flow in each of the past 5 years.
BCRX Yearly Net Income VS EBIT VS OCF VS FCFBCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With an excellent Return On Assets value of -18.12%, BCRX belongs to the best of the industry, outperforming 80.07% of the companies in the same industry.
Industry RankSector Rank
ROA -18.12%
ROE N/A
ROIC N/A
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCRX Yearly ROA, ROE, ROICBCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

BCRX has a Gross Margin of 97.23%. This is amongst the best in the industry. BCRX outperforms 96.12% of its industry peers.
BCRX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BCRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
BCRX Yearly Profit, Operating, Gross MarginsBCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

BCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BCRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BCRX has been increased compared to 5 years ago.
The debt/assets ratio for BCRX is higher compared to a year ago.
BCRX Yearly Shares OutstandingBCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BCRX Yearly Total Debt VS Total AssetsBCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

BCRX has an Altman-Z score of -2.35. This is a bad value and indicates that BCRX is not financially healthy and even has some risk of bankruptcy.
BCRX has a Altman-Z score of -2.35. This is comparable to the rest of the industry: BCRX outperforms 52.03% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.35
ROIC/WACCN/A
WACC9.27%
BCRX Yearly LT Debt VS Equity VS FCFBCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

BCRX has a Current Ratio of 2.63. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.63, BCRX is doing worse than 68.96% of the companies in the same industry.
BCRX has a Quick Ratio of 2.58. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BCRX (2.58) is worse than 68.61% of its industry peers.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 2.58
BCRX Yearly Current Assets VS Current LiabilitesBCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

BCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.57%, which is quite impressive.
The Revenue has grown by 36.00% in the past year. This is a very strong growth!
BCRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.99% yearly.
EPS 1Y (TTM)56.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.57%
Revenue 1Y (TTM)36%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%40.83%

3.2 Future

The Earnings Per Share is expected to grow by 40.34% on average over the next years. This is a very strong growth
BCRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.39% yearly.
EPS Next Y81.69%
EPS Next 2Y58.9%
EPS Next 3Y58.82%
EPS Next 5Y40.34%
Revenue Next Year25.39%
Revenue Next 2Y19.25%
Revenue Next 3Y17.46%
Revenue Next 5Y15.39%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BCRX Yearly Revenue VS EstimatesBCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
BCRX Yearly EPS VS EstimatesBCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCRX Price Earnings VS Forward Price EarningsBCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCRX Per share dataBCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

BCRX's earnings are expected to grow with 58.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.9%
EPS Next 3Y58.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (5/2/2025, 8:00:01 PM)

After market: 8.9 -0.03 (-0.34%)

8.93

+0.22 (+2.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24 2025-02-24/bmo
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners80.14%
Inst Owner Change0.24%
Ins Owners1.42%
Ins Owner Change16.77%
Market Cap1.87B
Analysts83.16
Price Target15.73 (76.15%)
Short Float %10.11%
Short Ratio5.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-65.05%
Min EPS beat(2)-123.6%
Max EPS beat(2)-6.5%
EPS beat(4)2
Avg EPS beat(4)-10.72%
Min EPS beat(4)-123.6%
Max EPS beat(4)66.23%
EPS beat(8)4
Avg EPS beat(8)-3.77%
EPS beat(12)6
Avg EPS beat(12)-10.52%
EPS beat(16)8
Avg EPS beat(16)-5.99%
Revenue beat(2)1
Avg Revenue beat(2)0.56%
Min Revenue beat(2)-0.92%
Max Revenue beat(2)2.03%
Revenue beat(4)3
Avg Revenue beat(4)4.09%
Min Revenue beat(4)-0.92%
Max Revenue beat(4)9.02%
Revenue beat(8)4
Avg Revenue beat(8)1.37%
Revenue beat(12)5
Avg Revenue beat(12)0.74%
Revenue beat(16)8
Avg Revenue beat(16)11.47%
PT rev (1m)0%
PT rev (3m)0.94%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)2.6%
EPS NY rev (1m)2.07%
EPS NY rev (3m)11.3%
Revenue NQ rev (1m)-0.38%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)3.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS2.15
BVpS-2.27
TBVpS-2.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.23%
FCFM N/A
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
F-Score3
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.21%
Cap/Sales 0.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.63
Quick Ratio 2.58
Altman-Z -2.35
F-Score3
WACC9.27%
ROIC/WACCN/A
Cap/Depr(3y)104.99%
Cap/Depr(5y)137.87%
Cap/Sales(3y)0.47%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.57%
EPS Next Y81.69%
EPS Next 2Y58.9%
EPS Next 3Y58.82%
EPS Next 5Y40.34%
Revenue 1Y (TTM)36%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%40.83%
Revenue Next Year25.39%
Revenue Next 2Y19.25%
Revenue Next 3Y17.46%
Revenue Next 5Y15.39%
EBIT growth 1Y97.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year325.94%
EBIT Next 3Y110.92%
EBIT Next 5YN/A
FCF growth 1Y45.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.32%
OCF growth 3YN/A
OCF growth 5YN/A